NASDAQ$PMVP
Pmv Pharmaceuticals Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
PMV Pharma reported financial results for Q3 2022 and provided a corporate update.
PMV Pharmaceuticals reported their Q3 2022 financial results, highlighting the continued advancement of the PYNNACLE study evaluating PC14586 and plans for the initiation of a clinical trial of PC14586 in combination with KEYTRUDA.
- Continued enrollment in the Phase 1/2 PYNNACLE trial of PC14586 in patients with advanced solid tumors.
- On track to initiate Phase 1b trial evaluating PC14586 in combination with KEYTRUDA in Q4 2022.
- Carol Gallagher, Pharm.D. appointed to the Board of Directors.
- Cash, cash equivalents, and marketable securities totaled $258.9 million as of September 30, 2022.
Headline financials
Revenue & EPS history
PMV Pharma · Revenue · Quarterly
$0
Forward guidance
The company is focused on advancing PC14586 and initiating a combination trial with KEYTRUDA.
Tailwinds
- Continued enrollment in PYNNACLE study.
- Planned update in the first half of 2023 for PYNNACLE study.
- On track to initiate Phase 1b trial evaluating PC14586 in combination with KEYTRUDA in Q4 2022.
- Observed promising, preliminary tumor-agnostic clinical efficacy with PC14586 monotherapy.
- Exploration of potential synergy between PC14586 and KEYTRUDA to improve patient outcomes.
Headwinds
- Success of clinical trials is subject to risks and uncertainties.
- Ability to execute on strategy and operate as an early clinical stage company is subject to risks.
- Clinical trials of PC14586 may differ from preclinical, preliminary or expected results.
- The Company's ability to fund operations is subject to risks.
- The impact that the current COVID-19 pandemic will have on the Company’s clinical trials, supply chain, and operations is a risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+2.7%
Avg return
Earnings day
+3.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
67%
14 / 21 earnings
Positive
+29.5%
Q2 2023
Best reaction
-18.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.0% | +8.0% | -10.7% | |
| Q3 2025 | +8.5% | +6.8% | -7.5% | |
| Q2 2025 | -4.1% | -6.6% | -3.9% | |
| Q1 2025 | +4.2% | +7.5% | +28.9% | |
| Q4 2024 | -3.6% | -10.2% | -27.0% | |
| Q3 2024 | +4.8% | +0.6% | -4.2% | |
| Q1 2024 | -5.6% | -0.9% | -23.1% | |
| Q4 2023 | +3.9% | +3.9% | -6.1% | |
| Q3 2023 | +7.5% | +19.9% | +24.2% | |
| Q2 2023 | +29.5% | +20.0% | -10.8% | |
| Q1 2023 | +11.9% | +14.7% | +8.5% | |
| Q4 2022 | -18.1% | -19.6% | -33.8% | |
| Q3 2022 | -3.7% | +11.2% | -2.6% | |
| Q2 2022 | +0.4% | -1.3% | -17.6% | |
| Q1 2022 | +2.2% | +9.0% | -13.7% | |
| Q4 2021 | +10.3% | +1.3% | +31.4% | |
| Q3 2021 | +0.4% | +2.4% | -1.6% | |
| Q2 2021 | -1.2% | -5.2% | -10.2% | |
| Q1 2021 | +12.7% | +15.6% | +18.5% | |
| Q4 2020 | +0.7% | -0.7% | -5.9% | |
| Q3 2020 | -5.1% | -5.2% | +40.3% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro